GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exelixis Inc (FRA:EX9) » Definitions » Cyclically Adjusted Book per Share

Exelixis (FRA:EX9) Cyclically Adjusted Book per Share : €3.79 (As of Mar. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Exelixis Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Exelixis's adjusted book value per share for the three months ended in Mar. 2024 was €6.636. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €3.79 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Exelixis's average Cyclically Adjusted Book Growth Rate was 23.80% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 34.50% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 90.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Exelixis was 179.80% per year. The lowest was -88.20% per year. And the median was -1.30% per year.

As of today (2024-06-08), Exelixis's current stock price is €20.18. Exelixis's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €3.79. Exelixis's Cyclically Adjusted PB Ratio of today is 5.32.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Exelixis was 223.00. The lowest was 4.94. And the median was 13.87.


Exelixis Cyclically Adjusted Book per Share Historical Data

The historical data trend for Exelixis's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exelixis Cyclically Adjusted Book per Share Chart

Exelixis Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.70 1.30 2.24 2.86 3.53

Exelixis Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 3.27 3.61 3.53 3.79

Competitive Comparison of Exelixis's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Exelixis's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Exelixis's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Exelixis's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Exelixis's Cyclically Adjusted PB Ratio falls into.



Exelixis Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Exelixis's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=6.636/131.7762*131.7762
=6.636

Current CPI (Mar. 2024) = 131.7762.

Exelixis Quarterly Data

Book Value per Share CPI Adj_Book
201406 0.012 100.560 0.016
201409 -0.233 100.428 -0.306
201412 -0.475 99.070 -0.632
201503 -0.692 99.621 -0.915
201506 -0.854 100.684 -1.118
201509 -0.292 100.392 -0.383
201512 -0.567 99.792 -0.749
201603 -0.612 100.470 -0.803
201606 -0.720 101.688 -0.933
201609 0.100 101.861 0.129
201612 0.292 101.863 0.378
201703 0.383 102.862 0.491
201706 0.450 103.349 0.574
201709 0.677 104.136 0.857
201712 0.813 104.011 1.030
201803 1.831 105.290 2.292
201806 2.227 106.317 2.760
201809 2.626 106.507 3.249
201812 3.774 105.998 4.692
201903 4.065 107.251 4.995
201906 4.351 108.070 5.305
201909 4.794 108.329 5.832
201912 4.978 108.420 6.050
202003 5.172 108.902 6.258
202006 5.271 108.767 6.386
202009 5.082 109.815 6.098
202012 4.957 109.897 5.944
202103 5.125 111.754 6.043
202106 5.386 114.631 6.192
202109 5.677 115.734 6.464
202112 6.136 117.630 6.874
202203 6.503 121.301 7.065
202206 7.030 125.017 7.410
202209 7.802 125.227 8.210
202212 7.251 125.222 7.631
202303 7.343 127.348 7.598
202306 7.286 128.729 7.458
202309 7.074 129.860 7.178
202312 6.856 129.419 6.981
202403 6.636 131.776 6.636

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Exelixis  (FRA:EX9) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Exelixis's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=20.18/3.79
=5.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Exelixis was 223.00. The lowest was 4.94. And the median was 13.87.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Exelixis Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Exelixis's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Exelixis (FRA:EX9) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exelixis Inc (FRA:EX9) » Definitions » Cyclically Adjusted Book per Share
Traded in Other Exchanges
Address
1851 Harbor Bay Parkway, Alameda, CA, USA, 94502
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Exelixis (FRA:EX9) Headlines

No Headlines